CG Oncology (CGON) Return on Sales (2023 - 2026)

CG Oncology has reported Return on Sales for 4 years, with the latest figure at 0.55% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 607.0% year-over-year to 0.55%; the trailing twelve-month figure through Mar 2026 stood at 0.37% (up 123.0% YoY), and the FY2025 full-year result was 0.4%, up 37.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.55%, down from 0.18% in the prior quarter.
• The five-year high for Return on Sales was 0.18% in Q4 2025, with the low at 165.51% in Q4 2023.
• Historically, Return on Sales has averaged 16.37% across 4 years, with a median of 1.2% in 2024.
• Annual changes were most pronounced in 2024 — Return on Sales soared 16481 bps — and 2025, when it tumbled 631 bps.
• CG Oncology's Return on Sales stood at 165.51% in 2023, then soared by 100 bps to 0.7% in 2024, then soared by 75 bps to 0.18% in 2025, then slumped by 212 bps to 0.55% in 2026.
• The last three Return on Sales figures came in at 0.55% (Q1 2026), 0.18% (Q4 2025), and 0.26% (Q3 2025), per Business Quant data.